A phase III trial of 1200 mg/d and 2400 mg/d for Parkinson's disease was discontinued early for lack of effectiveness in August 2011, and concluded, The investigational drug is unlikely to demonstrate efficacy over placebo for this indication.
A phase III trial of 1200 mg/d and 2400 mg/d ran until August 2011. This study was terminated and the summary concluded: The investigational drug is unlikely to demonstrate efficacy over placebo for this indication.